MedTrace Logo

Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.

NCT04731831 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-06-28

No results posted yet for this study

Summary

The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.

Conditions

  • Arthritis, Rheumatoid
  • Arthritis, Psoriatic
  • Spondylitis, Ankylosing

Sponsors & Collaborators

  • Aalborg University Hospital

    lead OTHER

Principal Investigators

  • Lene Dreyer, MD, Prof. · Department of Clinical Medicine, Aalborg University and Aalborg University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2025-12-01
Completion
2025-12-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04731831 on ClinicalTrials.gov